NASDAQ$VIR
Vir Biotechnology Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Vir Biotechnology reported its fourth quarter and full year 2024 financial results, highlighting progress in its chronic hepatitis delta and solid tumor programs.
Vir Biotechnology reported a net loss of $(104.6) million for Q4 2024, an improvement from $(116.0) million in Q4 2023. Total revenues for the quarter were $12.4 million, down from $16.8 million in the prior year. The company ended the year with $1.10 billion in cash, cash equivalents, and investments, providing a cash runway into mid-2027.
- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta is on track to begin in the first half of 2025.
- Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations, and EMA PRIME and Orphan Drug designations.
- Dual-masked T-cell engagers VIR-5818 and VIR-5500 showed compelling early clinical response signals and promising safety profiles in solid tumors.
- The company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$12.4K
Revenue by segment
Vir · $2.35M total across 2 segments · Q3 2023
- Grant revenue$6.74M+117.3%286.7%
- License & collaboration revenue-$4.39M-101.4%-186.7%
Forward guidance
Based on current operating plans, Vir Biotechnology expects its cash, cash equivalents, and investments to fund its operations into mid-2027.
Tailwinds
- Sufficient cash runway into mid-2027.
- Initiation of Phase 3 registrational program in chronic hepatitis delta in H1 2025.
- Further clinical progression of dual-masked T-cell engagers in solid tumors.
- Planned initiation of Phase 1 study for VIR-5525 in H1 2025.
- Focused prioritization and disciplined capital deployment.
Headwinds
- Future advancement in CHB contingent on securing a worldwide development and commercialization partner outside of China Territory.
- Potential for unexpected safety or efficacy data in clinical studies.
- Risks of unexpected costs, delays, or other hurdles.
- Difficulties in collaborating with other companies.
- Challenges in accessing manufacturing capacity and clinical site activation rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro